Prognostic and clinicopathologic value of ki-67 and profilin 1 immunohistochemical expression in primary pT1 urothelial bladder cancer

被引:7
作者
Culpan, Meftun [1 ,2 ,3 ,4 ,5 ]
Turan, Turgay [1 ,2 ,3 ]
Ozkanli, Sidika Seyma [4 ]
Zenginkinet, Tulay [4 ]
Kazan, Ozgur [5 ]
Ucar, Taha
Atis, Gokhan [5 ]
Caskurlu, Turhan [5 ]
Yildirim, Asif [5 ]
机构
[1] Okan Univ Hosp, Dept Urol, Istanbul, Turkey
[2] Okan Univ Hosp, Dept Pathol, Istanbul, Turkey
[3] Okan Univ Hosp, Dept Urol, Istanbul, Turkey
[4] Istanbul Med Univ, Fac Med, Istanbul, Turkey
[5] Turgutlu State Hosp, Dept Urol, Manisa, Turkey
关键词
Bladder cancer; Ki-67; profilin; 1; progression; recurrence; CARCINOMA; PROGRESSION; STAGE;
D O I
10.4103/jcrt.JCRT_408_19
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To investigate the prognostic and clinicopathologic value of Ki-67 and profilin 1 immunohistochemical expression in primary pT1 papillary urothelial bladder cancer. Materials and Methods: This study included 88 male and 13 female pT1 primary bladder cancer patients. Demographic characteristics, tumor histological grade, tumor number, presence of concomitant carcinoma in situ, tumor size, and status of recurrence or progression were recorded for each patient. Expression of Ki-67 and profilin 1 was evaluated by immunohistochemical analysis of paraffin-embedded tumor tissues. The Pearson's Chi-square test was used for the analysis of qualitative data, and the Kaplan-Meier method and the log-rank test were used for the survival analysis. Results: In the mean follow-up period of 52 months, 52 (51.5%) patients experienced recurrence, 24 (23.8%) patients experienced progression, and 17 (16.8%) patients died from bladder cancer-related causes. Ki-67 expression was significantly associated with tumor histological grade (P = 0.001). In multivariate analysis, Ki-67 positivity had significantly worse outcome for recurrence (P = 0.006) and mortality (P = 0.022). Ki-67-positive (Ki-67 index >= 15%) patients had shorter recurrence-free (P = 0.003), progression-free (P = 0.002), and cancer-specific (P = 0.003) survival. However, no statistically significant relationship was found between profilin 1 expression and clinicopathologic features and prognosis. Conclusions: Ki-67 is a highly predictive biomarker for recurrence-free, progression-free, and cancer-specific survival in pT1 bladder cancer patients, in whom prediction of recurrence and progression are difficult. Ki-67 expression can be safely combined with other prognostic factors. However, in pT1 bladder cancer patients, no significant relationship was found between profilin 1 expression and tumor characteristics or prognostic parameters.
引用
收藏
页码:434 / 442
页数:9
相关论文
共 20 条
[1]   Profilin1 biology and its mutation, actin(g) in disease [J].
Alkam, Duah ;
Feldman, Ezra Z. ;
Singh, Awantika ;
Kiaei, Mahmoud .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2017, 74 (06) :967-981
[2]   EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016 [J].
Babjuk, Marko ;
Boehle, Andreas ;
Burger, Maximilian ;
Capoun, Otakar ;
Cohen, Daniel ;
Comperat, Eva M. ;
Hernandez, Virginia ;
Kaasinen, Eero ;
Palou, Joan ;
Roupret, Morgan ;
van Rhijn, Bas W. G. ;
Shariat, Shahrokh F. ;
Soukup, Viktor ;
Sylvester, Richard J. ;
Zigeuner, Richard .
EUROPEAN UROLOGY, 2017, 71 (03) :447-461
[3]  
Ben Abdelkrim Soumaya, 2014, J Immunoassay Immunochem, V35, P358, DOI 10.1080/15321819.2014.899254
[4]   Combination of CK20 and Ki-67 Immunostaining Analysis Predicts Recurrence, Progression, and Cancer-Specific Survival in pT1 Urothelial Bladder Cancer [J].
Bertz, Simone ;
Otto, Wolfgang ;
Denzinger, Stefan ;
Wieland, Wolf F. ;
Burger, Maximilian ;
Stoehr, Robert ;
Link, Stefan ;
Hofstaedter, Ferdinand ;
Hartmann, Arndt .
EUROPEAN UROLOGY, 2014, 65 (01) :218-226
[5]   Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: Do risk factors define feasibility of bladder-sparing approach? [J].
Denzinger, Stefan ;
Fritsche, Hans-Martin ;
Otto, Wolfgang ;
Blana, Andreas ;
Wieland, Wolf-Ferdinand ;
Burger, Maximilian .
EUROPEAN UROLOGY, 2008, 53 (01) :146-152
[6]   Ki-67 is an independent indicator in non-muscle invasive bladder cancer (NMIBC); Combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC [J].
Ding Weihong ;
Gou, Yuancheng ;
Sun, Chuanyu ;
Xia, Guowei ;
Wang, Hong ;
Chen, Zhongqing ;
Tan, Jun ;
Xu, Ke ;
Ding, Qiang .
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2014, 32 (01) :42.e13-42.e19
[7]   Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 [J].
Ferlay, Jacques ;
Soerjomataram, Isabelle ;
Dikshit, Rajesh ;
Eser, Sultan ;
Mathers, Colin ;
Rebelo, Marise ;
Parkin, Donald Maxwell ;
Forman, David ;
Bray, Freddie .
INTERNATIONAL JOURNAL OF CANCER, 2015, 136 (05) :E359-E386
[8]   Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium [J].
Goebell, Peter J. ;
Knowles, Margaret A. .
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2010, 28 (04) :409-428
[9]  
Goyal S, 2014, UROL J, V11, P1238
[10]   The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours [J].
Humphrey, Peter A. ;
Moch, Holger ;
Cubilla, Antonio L. ;
Ulbright, Thomas M. ;
Reuter, Victor E. .
EUROPEAN UROLOGY, 2016, 70 (01) :106-119